10 results about "Nervous disease" patented technology

kinase inhibitor. 20 26 20 54 07 08 J ul 2 02 6 A B S T R A C T 2 0 2 6 2 0 5 4 0 7 0 8 J u l 2 0 2 6 k i n a s e i n h i b i t o r .

This disclosure relates to reagents such as antisense oligonucleotides that bind to nucleic acids encoding cryptic exons, thereby inhibiting or preventing ELAVL3 cryptic splicing, and to their use in the treatment or prevention of TDP-43-related neurodegenerative or neurological diseases or conditions associated therewith. In some embodiments, the antisense oligonucleotide is a nucleobase polymer capable of reducing the level or expression of intracellular ELAVL3 cryptic exon RNA and increasing or restoring the expression of functional ELAVL3 protein without substantially incorporating the cryptic exon RNA peptide sequence.

Provided herein are ATXN2 RNAi agents and compositions comprising an ATXN2 RNAi agent. Also provided herein are methods of using the ATXN2 RNAi agents or compositions comprising an ATXN2 RNAi agent for reducing ATXN2 expression, and / or treating ATXN2-associated neurological disease in a subject.

The present technology relates to a genus of compounds comprising a subunit of arimoclomol covalently linked to a subunit of miglustat. The present technology further relates to compositions comprising said compounds and method of treating neurological diseases and disorders using said compounds.

Soluble proteins and extracellular vesicles (EVs) produced by optic nerve lamina region neural progenitor cells (ONLR-NPCs) are provided. Such proteins and EVs include growth factors and survival factors that can be used in the treatment of optic nerve diseases, such as glaucoma. Also provided are methods of treating or preventing optic nerve diseases, such as glaucoma, using ONLR-NPC-based compositions.

Provided herein are ATXN2 RNAi agents and compositions comprising an ATXN2 RNAi agent. Also provided herein are methods of using the ATXN2 RNAi agents or compositions comprising an ATXN2 RNAi agent in reducing ATXN2 expression and / or treating ATXN2-associated neurological disease.

In various aspects and embodiments, compositions and methods for identifying patients in need of improved cognition and / or treatment of neurodegenerative diseases in patients and treating such patients are provided. More specifically, in some embodiments, the present disclosure comprises administering a beta-AR agonist (such as a beta agent) and a peripherally acting beta blocker (PABRA) to a patient in need thereof.

This invention discloses a pharmaceutical composition comprising a compound of formula I and dextroborneol, which has shown unexpected effects in treating cerebrovascular diseases and central nervous system diseases.

The application discloses a brain effect connection learning and analysis method based on multi-source space-time collaborative modeling, and belongs to the technical field of brain science and medical image processing. The method comprises the following steps: receiving multi-source brain time sequence data, and constructing a unified space-time representation of brain regions; performing space correlation modeling and time collaborative processing on the brain region level time sequence to obtain a unified space-time feature representation; dynamically modeling the unified space-time feature representation through a multi-source collaborative learning mechanism to obtain a brain region fusion feature representation; constructing a connection relationship learning model based on the brain region fusion feature representation, determining the connection relationship between brain regions through a structure generation and optimization process, and obtaining a brain effect connection network. Through unified space-time representation modeling, a multi-source collaborative learning mechanism and a structure feedback optimization process, the application effectively improves the accuracy, stability and interpretability of brain effect connection modeling, and can be widely applied to the fields of brain function analysis, auxiliary diagnosis of neurological diseases and brain state recognition.